INTRODUCTION
FluMist, a live attenuated influenza virus (LAIV) vaccine, is used in healthy children and adults (2-49 years of age) (Fiore et al., 2009) . It induces neutralizing serum antibodies against the homosubtypic strain and also can stimulate strong heterosubtypic immunity via T cell responses targeted to the shared regions of internal proteins (Powell et al., 2007) . The six segments encoding internal proteins (PB2, PB1, PA, NP, M and NS) of currently used LAIV vaccines are derived from the donor strains (A/Ann Arbor/6/60
[AA60] H2N2 or B/Ann Arbor/1/66, AAca) and are reassorted with the haemagglutinin (HA) and the neuraminidase (NA) from World Health Organization recommended circulating strains by reverse genetics (Chen et al., 2006; Jin et al., 2003) . Four major loci [PB1(1195) (K391E), PB1 (1766) (E581G), PB2(821) (N265S) and NP(146) (D34G)] are responsible for the characteristic cold-adapted (ca), attenuated (att) and temperature-sensitive (ts) phenotypes (Jin et al., 2003) . The AAca virus was restricted in replication in the respiratory tract of mice and ferrets (Chen et al., 2010) . These mutations introduced into the genetic background of PR8 can also confer the phenotype of ca, att and ts in both ferrets and mice (Huber et al., 2009; Jin et al., 2004) .
Since neutralizing or HA inhibition antibodies are absent in heterosubtypic challenge, it is believed that CD8 + T cells play a major role in heterosubtypic immunity (Grant et al., 2016; Powell et al., 2007; Thomas et al., 2006; Wang et al., 2015b) . T cell depletion experiments in both X31-primed and ca.A/Alaska-primed mice indicated that CD8 + T cells were the major contributors to protection as measured at day 8 post-challenge, although CD4 + T cells also contributed to this process (Powell et al., 2007) . It is, however, unknown whether the immunization dose of LAIV affects the magnitude and functional quality of influenza-specific CD8 + T cell responses and establishment of the memory pools. It is possible that high doses of LAIV can induce numerically more CD8 + T cells and thus subsequently provide superior heterosubtypic protection, or alternatively a lowdose LAIV could recruit fewer CD8 + T cells to combat the heterosubtypic influenza infection. Furthermore, could the LAIV immunization dose affect the number of long-lasting tissue resident memory T (T RM ) cells in the lungs? In this study, we immunized mice intranasally (i. n.) with different doses (1Â10 2 and 2Â10 5 f.f.u. per mouse) of live-attenuated PR8 virus (PR8 ts, H1N1). We subsequently challenged those mice with the heterosubtypic X31 (H3N2) virus, which expresses distinct HA and NA, but shares the same six internal genes as PR8. In this way, the heterosubtypic PR8 (H1N1)fiX31 (H3N2) challenge allows the assessment of the secondary CD8 + T cell responses post-vaccination, in the absence of cross-reactive antibodies (Baker et al., 2013) .
RESULTS

LAIV has an attenuated phenotype in mice
Temperature-sensitive PR8 virus was generated as described previously (Huber et al., 2009) and viable viral particles were rescued from allantoic fluid of inoculated eggs. PR8 ts demonstrated increased temperature sensitivity when eggs were incubated at either 33 or 37 C (Fig. 1a) , with significantly lower titres obtained at higher temperature following 48 h incubation (P<0.05). When compared to the wild-type virus (PR8-wt), PR8 ts displayed much slower growth kinetics at m.o.i. of 0.01, when grown in Madin-Darby canine kidney (MDCK) monolayers at 37 C over 48 h (Fig. 1b) . A low dose of 10 2 f.f.u. and a high dose of 2.5Â10 5 f.f.u. were used for in vivo intranasal infection of C57B6 mice, which confirmed the attenuated phenotype of PR8 ts. At both doses, mice showed only transient body weight loss of 5 % with quick recovery, whereas mice infected with 10 2 f.f.u. of PR8-wt lost on average 20 % body weight within 9 days without signs of recovery (Fig. 1c) . Since PR8 ts virus cannot replicate efficiently in upper respiratory tract and in lungs, we investigated how the viral dose of PR8 ts affects generation of CD8 + T cell responses and subsequent protection from virulent challenge.
Comparable primary or memory CD8
+ T cell responses, but not immunodominance hierarchy, with different vaccination doses
We investigated primary CD8 + T cell responses on day 10 post-vaccination and memory responses at 6 weeks postvaccination in order to determine whether vaccination dose can lead to differences in specific antiviral responses. On day 10 post-vaccination, we assessed the magnitude [number of tetramer-positive CD8 + T cells (Fig. 2a, b) ] and functional quality [number of IFNg-producing CD8 + T cells (Fig. 2c) Kedzierska et al., 2006b) . Our data show that, while the numbers of influenza-specific CD8 + T cells in lungs increase with the higher LAIV dose (Fig. 2a, c, d , left panel), the numbers of D b NP 366 -specific CD8 + T cells in the spleen decrease with increasing vaccine dose (Fig. 2a, c, Valkenburg et al., 2010) We then investigated memory responses at 6 weeks after priming with PR8 ts (Fig. 3) (Fig. 3b) . These findings support our previous studies on the the early establishment of influenza-specific CD8 + T cell memory during influenza virus infection Kedzierska et al., 2007) .
To determine whether the numerically higher CD8 + T cell response induced by the low-dose immunization was due to higher inflammatory milieu, we measured cytokine levels induced after primary immunization with low/high dose at days 3 and 10. Our data ( Fig. 3d) showed that the cytokine levels induced by a high dose (2.5Â10 5 f.f.u.) in lungs at days 3 and 10 after vaccination were higher than those induced with the lower dose (1Â10 2 f.f.u.) and were not associated with different numbers of antigen-specific CD8 + T cell responses elicited by those doses.
Priming with different doses of PR8 ts leads to similar efficient recall response As described above, vaccination with a lower dose of 10 2 f.f.u. of PR8 ts generated a significantly larger pool of virus-specific memory CD8 + T cells in the spleen (Fig. 3a) . To investigate whether this could affect secondary recall CD8 + T cell responses following virulent challenge, C57B6 mice were vaccinated i.n. with different doses of PR8 ts, and PBS-primed mice were included as a control. Six weeks following immunization, all experimental groups were challenged with 10 4 p.f.u. of X31 influenza virus. BAL and spleen were examined for virus-specific CD8 PA 224 -specific CD8 + T cells on day 5 in BAL and spleens of immunized animals compared to PBS controls (Fig. 4a ). Those CD8 + T cells also produced much higher levels of IFNg early in infection (Fig. 4b) . Later during the course of infection (day 8), there was no difference between immunized and control groups, and in the case of immunized animals, the recall pool of CD8 + T cells already started diminishing, suggesting earlier viral clearance and removal of antigenic stimulation. However, both immunized groups mounted equivalent CD8 + T cell recall responses indicating that immunization dose does not affect the expansion of virus-specific memory cells at the site of infection.
We also investigated whether different LAIV doses could reduce influenza virus-mediated inflammation. To do this, the cytokine milieu at the site of infection was assessed in lung homogenates using cytokine bead array (CBA). A panel of cytokines and chemokines, including IL-6, IL-10, IL-12, IFNg, TNF and monocyte chemotactic protein-1 (MCP-1, CCL-2), was evaluated on days 3 (Fig. 5a ) and 6 ( Fig. 5b) post-challenge. Our data indicate that immunized animals can control the inflammation much better than unvaccinated control animals, as demonstrated by reduced levels of the majority of cytokines tested (IL-6, IFNg, TNFa and MCP-1 at day 6, P<0.05, Fig. 5b ), particularly IL-6, which is a well-known factor promoting pulmonary inflammation. Interestingly, only MCP-1 was significantly reduced differentially at day 3 after infection in high-dose LAIV recipients, compared with those that received low-dose LAIV, which was consistent with the number of macrophages recruited to the site of infection at day 3 (Fig. 5c ). Concn (pg ml + T cell populations in the spleen and lungs. Dot plots from individual mice were combined into a cumulative display. (d) Cytokine levels were measured by cytokine bead array (CBA) at days 3 and 10 after primary infection with low-dose 10 2 f.f.u. PR8 ts and high-dose 2.5Â10 5 f.f.u. PR8 ts (n=5 per group within an experiment). Statistics between groups were performed using Mann-Whitney test.
CD8 + T cells and LAIV vaccination
PR8 ts group (Fig. 6b ). Viral load was examined on days 3, 5, 6 and 8 post-challenge in lung homogenates. At day 5, the viral titres in the lungs of vaccinated groups were significantly lower than those in control mice (P<0.0001), while on day 6, the virus was undetectable in the lungs of immunized animals, but still detectable in the control group. On day 8 post-challenge, the majority of mice had lung viral titres below the level of detection. On day 5 post-challenge, mice vaccinated with 10 2 f.f.u. LAIV had significantly increased levels of virus, compared with mice that received 2.5Â10 5 f.f.u. (P<0.001). Delayed viral clearance during antiviral response can usually be attributed to delayed recruitment of influenza-specific CD8 + T cells to the site of infection (Marois et al., 2015) , which was not observed in this case (Fig. 4) . As the magnitude of CD8 + T cell responses did not correlate with viral clearance across different immunization doses, we investigated antibody levels triggered by different doses of PR8 ts vaccine. Our ELISA results show that antibody titres against homologous PR8 HA protein were dose dependent, with antibody titres induced by the higher 2.5Â10 5 f.f.u. dose detected at nearly 160-fold greater level than those induced by 10 2 f.f.u. (Fig. 6c) . We then tested antibody titres against heterologous X31 HA protein and found no difference between doses of LAIV (Fig. 6d) . It has been reported that antibodies raised against the X31 virus do not significantly cross-react with the PR8 virus; nonetheless, X31-specific antibodies provide some protection against PR8 infection (RangelMoreno et al., 2008) . Our data suggest that the same holds true when antibodies are raised against PR8.
DISCUSSION
In this study, we observed that different LAIV doses elicit distinct influenza-specific CD8 + T cell responses in lungs and spleens, but unexpectedly not in BAL. Virus-specific CD8 + T cell responses typically fall into reproducible hierarchies, with particular epitopes eliciting either immunodominant (numerically high) or subdominant (numerically low) responses after the viral challenge. In the B6 model of influenza virus infection, CD8 + T cell responses specific for epitopes derived from the nucleoprotein ) and acid polymerase ) proteins dominate during the primary acute immune response, with D b NP 366 + CD8 + T cells being numerically larger on day 10 after infection (Cukalac et al., 2014; Kedzierska et al., 2006a) Interestingly, the immunodominance hierarchy at the acute time after immunization was affected by the LAIV dose; however, these differences disappeared at 6 weeks post-vaccination. We found that sufficient numbers of specific CD8 + T cells were generated for recall and protection of mice against heterosubtypic PR8 (H1N1)fiX31 (H3N2) . Mean values were plotted, and error bars represent SEM, n=5 biological replicates within one experiment; statistics between groups were performed using Mann-Whitney test (***P<0.001).
CD8
+ T cells and LAIV vaccination challenge (X31 virus shared the same six internal genes as PR8 virus). Thus, our study indicates that immunization with even a low dose of LAIV can establish a protective influenza-specific CD8 + T cell memory pool in lungs.
Currently, intranasal immunization with cold-adapted live attenuated influenza vaccine is a very efficient way to induce cellular CD8 + T cell immunity against the virus (Carter & Curran, 2011) . Therefore, LAIV has been postulated to induce cross-protective immunity against heterologous strains of influenza. Studies in mice demonstrated that priming with LAIV induces heterosubtypic immunity, and while it does not lead to sterile immunity, it results in faster viral clearance and protects against weight loss associated with infection (Lanthier et al., 2011; Powell et al., 2007) . CD8 + T cells are thought to be responsible for the observed protection, with some involvement from CD4 + T cells, while B cells were shown to be non-essential (Powell et al., 2007) . Studies in humans vaccinated with LAIV indicated that the vaccine leads to development of type 1 memory responses leading to T cell recruitment via production of IFNg and expression of chemokines (Lanthier et al., 2011) . More recently, Harty's group (Slütter et al., 2013) showed that LAIV vaccination leads to generation of cross-protective CD8 + T cells, but their numbers are inadequate to control infection with heterosubtypic viral strain. This, however, can be rectified by additional boosting which leads to increased numbers of virus-specific T cells and results in memory pools sufficient to protect against heterologous challenge.
In our study, we have investigated whether different doses of LAIV can lead to different numbers of virus-specific CD8 + T cells and whether those T cells can effectively protect against heterosubtypic challenge. A previous study showed that increasing a dose of PR8-wt by an intraperitoneal injection route could not only expand the CD8 + T cell response but also change the immunodominance hierarchy (Luciani et al., 2013) . Two different doses of LAIV used in this study led to generation of comparable numbers of tetramer-positive CD8 + T cells in both lungs and spleens of vaccinated animals. The notable difference was a slight change in immunodominance hierarchy 10 days following priming, where upon immunization with a lower dose, increased numbers of D b NP 366 -specific CD8 + T cells were induced in the spleen, while a higher dose led to increased numbers of D b PA 224 -specific CD8 + T cells in the lungs of immunized animals. To some degree, this is in agreement with the above-mentioned study (Luciani et al., 2013) , where increasing the viral dose via intraperitoneal delivery led to a switch in immunodominance from NP 366 to PA 224 in the spleen. Interestingly, these differences were alleviated in the lungs at a later time point (6 weeks post-priming), while spleens of mice immunized with a lower dose of LAIV showed higher numbers of NP 366 -specific memory CD8 + T cells.
Despite the differences observed in the spleen, there was no difference in the immunodominance hierarchy or numbers of virus-specific CD8 + T cells in the lungs 6 weeks postimmunization. Since the lung is the actual site of infection, we examined the formation of resident memory CD8 + T cells. Lung T RM cells provide the first line of defence against respiratory viruses and are able to efficiently restrict early viral replication by providing a rapid source of cytokines, particularly IFNg (McMaster et al., 2015) . Different doses of LAIV vaccine were able to induce formation of T RM cells, but we did not observe any differences between low and high immunization dose, in either numbers of virus specific T RM or overall T RM numbers. At 6 weeks post-priming, the numbers of virus-specific T RM cells were relatively low, which is consistent with their non-proliferative nature.
A recent report by Slütter et al. (2013) indicated that single immunization of Balb/c mice with FluMist, 40 days prior to heterosubtypic challenge, did not induce sufficient numbers of cross-protective CD8 + T cells to control infection. Our data indicate that a single immunization with LAIV, either low or high dose, was able to protect mice against nonhomologous challenge (6 weeks post-immunization). This has been demonstrated by a smaller and transient weight loss and accelerated viral clearance from the lungs of immunized animals. A possible explanation for the observed difference could be the vaccination-challenge strategies, which differed between the two studies. While Slütter et al. (2013) primed with 2010-2011 FluMist vaccine containing H1N1, H3N2 and influenza B strains and challenged with PR8, we used PR8 (H1N1)-based LAIV for priming and challenged with X31 (H3N2) virus, which shared the same six internal genes as PR8. Despite this difference, it was clear that sufficient numbers of virus-specific heterosubtypic protective CD8 + T cells were induced in our study and protection was achieved without a need for boosting. Interestingly, the higher immunization dose led to more rapid virus clearance from lungs, which manifested itself on day 5 post-challenge. This phenomenon could not be linked to increased numbers of virus-specific CD8 + T cells or T RM cells, increased levels of cytokines such as IFNg or higher levels of heterosubtypic, neutralizing antibodies. None of these immunological parameters significantly differed between the two immunization doses, though non-neutralizing antibodies against the PR8 virus were found to be significantly higher in the high-dose immunized group. It seems that the higher LAIV vaccination dose also appears to induce other factors, which contribute to further reduction in inflammation and viral load after the secondary virus infection. Powell et al. (2007) reported that CD8 + T cells are thought to be mainly responsible for heterosubtypic protection, with some involvement from CD4 + T cells, while B cells were shown to be non-essential. Conversely, others reported that the antibodies against conserved regions of HA, NA, NP, M1 and M2 could also help cross-reactive protection (Gerhard et al., 1997; Khattak et al., 1999; LaMere et al., 2011; Neirynck et al., 1999; Slepushkin et al., 1995) , which highlights the importance of B cells and antibodies in the recovery of mice from influenza virus infection (Rangel-Moreno et al., 2008) . Additionally, non-neutralizing antibodies could facilitate the expansion of responding memory CD8 + T cells and promote recovery from lethal heterosubtypic influenza challenge (Rangel-Moreno et al., 2008) . The intranasal immunization with H5N1-att vaccine provided broad cross-protection against a range of H5N1 viruses in mice and ferrets, mainly due to the protection specific to the H5 HA (Suguitan et al., 2006) ; however, our data showed that the high dose and low dose induced similar cross-reactive antibodies against X31 HA. Furthermore, there has been convincing evidence that non-neutralizing antibodies are associated with the protection against heterosubtypic influenza viruses (Carragher et al., 2008; Rangel-Moreno et al., 2008) , potentially related to the elimination of influenza virus via FcR-mediated phagocytosis (Huber et al., 2001) , which might be a potential explanation for our observed differences in virus clearance and inflammation reduction caused by different dose LAIV vaccination.
METHODS
Infection of mice and characterization of PR ts in MDCK cells.
C57B6 mice were bred and housed at the Department of Microbiology and Immunology, University of Melbourne. Experiments were approved and conducted under guidelines set by the University of Melbourne Animal Ethics Committee. Mice were anaesthetized by inhalation of methoxyflurane and i.n. infected with 1.0Â10 2 and 2.5Â10 5 p.f.u. (f.f.u.) of LAIV (PR8 ts; H1N1) in 30 µl of PBS. We based our definition of the high-dose (2.5Â10 5 f.f.u.) and low-dose (10 2 f.f.u.) amounts in this study on the clinical dose of FluMist (10 7 p.f.u.) used in an adult human with an average weight of 75 kg and extrapolating this to a mouse with an average weight of 20 g (10 3 p.f.u.).
Mice were challenged i.n. 6 weeks later with 1Â10 4 p.f.u. of X31 (H3N2) virus in 30 µl PBS. Lungs were harvested for viral load and viral load was determined by plaque assay (Matrosovich et al., 2006) . As it is difficult to observe plaque formation using PR8 ts in a standard plaque assay, we used a focus assay as a means of measuring viral titres. Therefore, for the viral stock (PR8 ts) titration and replication kinetics comparison between PR8 and PR8 ts in MDCK cells, viral levels were determined by focus assay (focus-forming assay), as previously described (Wang et al., 2010) . PA 224-233 tetramer conjugated to PE or allophycocyanin . Results were analysed using FlowJo software. Lungs for T RM analysis were processed as previously described (Kedzierski et al., 2015; Quiñones-Parra et al., 2016; Wakim et al., 2015) .
Cytometric bead analysis. The CBA flex set (BD Biosciences) was used as per manufacturer's instructions to determine the cytokine concentrations of BAL supernatant. Data were acquired using FACSCantoII and analysis was by FCAP Array software (Soft Flow).
Influenza-specific antibody. Sera were prepared from blood taken 4 weeks after immunization. ELISA was performed in 96-well plates as previously described (Wang et al., 2015a) .
Statistical analyses. ANOVA and P values in this study were obtained using one-way ANOVA non-parametric analyses and Tukey's post-hoc range tests or Student's t-test (GraphPad Software).
